Trials / Completed
CompletedNCT03127956
A Long-term Safety Study of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
An Open-Label Study Assessing Long-Term Safety of Olumacostat Glasaretil Gel in Subjects With Acne Vulgaris
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 748 (actual)
- Sponsor
- Dermira, Inc. · Industry
- Sex
- All
- Age
- 9 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess the long-term safety of Olumacostat Glasaretil gel, 5.0% in patients with acne vulgaris
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Olumacostat Glasaretil Gel, 5.0% | Gel containing Olumacostat Glasaretil |
Timeline
- Start date
- 2017-03-21
- Primary completion
- 2018-04-27
- Completion
- 2018-04-27
- First posted
- 2017-04-25
- Last updated
- 2021-07-20
- Results posted
- 2019-02-05
Locations
94 sites across 3 countries: United States, Australia, Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03127956. Inclusion in this directory is not an endorsement.